NFKB1 and acute myeloid leukemia: Thus, one explanation for the difference of HO-1 levels in cells with FLIPL-targeted knockdown compared to control cells, is that removing FLIPL reduces the active NF-κB levels in human AML cells, thus removing its negative influence on the HO-1 promoter.